Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)

The Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) funding opportunity is administered by the National Institutes of Health through the National Institute of Mental Health, with participation from the National Institute on Drug Abuse. This program is part of the broader federal research mission to improve the understanding and treatment of mental health disorders. The initiative specifically targets the advancement of clinical trial methodologies involving rapid-acting psychotropic drugs such as psilocybin, LSD, ketamine, and MDMA. These compounds have demonstrated the potential to provide rapid and sustained therapeutic effects for mental health conditions, but their evaluation presents unique scientific and methodological challenges that this grant aims to address. The purpose of this funding opportunity is to support rigorous clinical trials that isolate and clarify the therapeutic mechanisms of RAPIDs. Emphasis is placed on improving trial design to reduce bias, enhance reproducibility, and strengthen the interpretability of findings. Applicants are expected to address issues such as expectancy effects, placebo response challenges, maintaining blinding integrity, and variability in adjunctive psychotherapy delivery. The program also requires the integration of neurobiological measures to objectively assess treatment response, ensuring that findings can be attributed directly to the intervention rather than external or subjective factors. Funding is provided through the R01 Research Project Grant mechanism, with budgets not capped but required to reflect the actual needs of the proposed research. The total anticipated funding includes up to 5,000,000 dollars from NIMH to support approximately five awards and an additional 500,000 dollars from NIDA for one award. Projects may span up to five years depending on scope. There is no cost sharing or matching requirement for this opportunity. Funds may be used to support clinical trial design, participant recruitment, data collection, neurobiological assessments, and related research activities aligned with the program’s objectives. Eligibility for this opportunity is broad and inclusive of a wide range of U.S.-based organizations. Eligible applicants include public and private institutions of higher education, nonprofit organizations, for-profit entities including small businesses, and various levels of government entities including state, local, and tribal governments. Foreign organizations and non-U.S. components of domestic organizations are not eligible. Principal investigators must possess the necessary expertise and institutional support, and all applicants must complete required federal registrations including SAM, Grants.gov, and eRA Commons prior to submission. The application process requires submission through Grants.gov using NIH-approved systems such as ASSIST or Workspace. Applicants must follow the NIH Research Application Guide and include detailed components such as a Research Strategy, Data Management and Sharing Plan, and Human Subjects and Clinical Trials Information. Proposals must explicitly describe methodological approaches, neurobiological outcome measures, and regulatory considerations such as FDA Investigational New Drug status. Applications are subject to a two-stage review process involving scientific peer review and advisory council evaluation, with criteria focusing on significance, innovation, rigor, feasibility, and investigator expertise. Key dates for this opportunity include an earliest submission date of September 10, 2026, and a final application deadline of October 10, 2026. Applications must be submitted by 5:00 PM local time of the applicant organization. Peer review is expected in March 2027, followed by advisory council review in May 2027, with the earliest project start date projected for July 2027. This is a one-time funding announcement with a defined expiration date of October 11, 2026, and does not indicate a recurring cycle. Applicants are encouraged to engage with program staff early in the process for guidance and alignment with program priorities.

Ensure rigorous trial design addressing expectancy effects and blinding integrity; include validated neurobiological outcome measures; clearly justify dosing and psychotherapy protocols